A Common Ground For rDNA Adversaries

It’s not easy, at first sight, to discern signs of ideological harmony between biologists who are working toward the environmental dissemination of genetically altered organisms and “activists” who are deeply apprehensive about the idea. Look more closely, however, and one argument appears as a possible basis for unity: the need for far greater investment in the ecological research necessary for prudent development of this novel range of technologies. As reflected in the ag

Written byBernard Dixon
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

It’s not easy, at first sight, to discern signs of ideological harmony between biologists who are working toward the environmental dissemination of genetically altered organisms and “activists” who are deeply apprehensive about the idea. Look more closely, however, and one argument appears as a possible basis for unity: the need for far greater investment in the ecological research necessary for prudent development of this novel range of technologies.

As reflected in the agenda for the First International Conference on the Release of Genetically Engineered Microorganisms (REGEM 1), which opens April 5 in Cardiff, Wales, the potential applications of organisms carrying recombinant DNA in agriculture, medicine and other domains are extremely impressive in their range and promise. Yet at least some of those rewards may be slow to accrue unless much greater effort is put into fundamental environmental studies that will provide guidance for both scientists and regulatory authorities.

“It is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies